Literature DB >> 24651559

Massachusetts General Hospital SAFER criteria for clinical trials and research.

Martin Desseilles1, Janet Witte, Trina E Chang, Nadia Iovieno, Christina Dording, Heidi Ashih, Maren Nyer, Marlene P Freeman, Maurizio Fava, David Mischoulon.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24651559     DOI： 10.1097/HRP.0b013e3182a75cc7

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN： 1067-3229            Impact factor:   3.732


× No keyword cloud information.
  8 in total

1.  The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder.

Authors:  Maurizio Fava
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

2.  EPA and DHA as markers of nutraceutical treatment response in major depressive disorder.

Authors:  Kiki P van der Burg; Lachlan Cribb; Chee H Ng; Joseph Firth; Diana Karmacoska; David Mischoulon; Gerard J Byrne; Chad Bousman; Con Stough; Jenifer Murphy; Georgina Oliver; Michael Berk; Jerome Sarris
Journal:  Eur J Nutr       Date:  2019-09-25       Impact factor: 5.614

3.  Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.

Authors:  Laura E Dichtel; Linda L Carpenter; Maren Nyer; David Mischoulon; Allison Kimball; Thilo Deckersbach; Darin D Dougherty; David A Schoenfeld; Lauren Fisher; Cristina Cusin; Christina Dording; Nhi-Ha Trinh; Paola Pedrelli; Albert Yeung; Amy Farabaugh; George I Papakostas; Trina Chang; Benjamin G Shapero; Justin Chen; Paolo Cassano; Emily M Hahn; Elizabeth M Rao; Roscoe O Brady; Ravinder J Singh; Audrey R Tyrka; Lawrence H Price; Maurizio Fava; Karen K Miller
Journal:  Am J Psychiatry       Date:  2020-07-14       Impact factor: 18.112

4.  S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.

Authors:  Jerome Sarris; Jenifer Murphy; Con Stough; David Mischoulon; Chad Bousman; Patricia MacDonald; Laura Adams; Sonia Nazareth; Georgina Oliver; Lachlan Cribb; Karen Savage; Ranjit Menon; Suneel Chamoli; Michael Berk; Chee H Ng; Gerard J Byrne
Journal:  Psychopharmacology (Berl)       Date:  2019-11-11       Impact factor: 4.530

5.  Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials.

Authors:  Marlene P Freeman; James Pooley; Martina J Flynn; Lee Baer; David Mischoulon; David Mou; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2017-04       Impact factor: 3.153

6.  A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors:  G I Papakostas; K Johe; H Hand; A Drouillard; P Russo; G Kay; R Kashambwa; B Hoeppner; M Flynn; A Yeung; M A Martinson; M Fava
Journal:  Mol Psychiatry       Date:  2019-01-09       Impact factor: 15.992

Review 7.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

8.  REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases.

Authors:  Clotilde Guidetti; Giulia Serra; Luca Pani; Marco Pappagallo; Gino Maglio; Monia Trasolini; Sara De Martin; Andrea Mattarei; Francesco Bifari; Franco Folli; Paolo L Manfredi; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2022-08-06       Impact factor: 3.118
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.